Rosemary Mazanet
Director/Board Member presso ONCTERNAL THERAPEUTICS, INC.
Patrimonio netto: 547 476 $ in data 29/02/2024
Profilo
Rosemary Mazanet ha fondato Apelles Investment Management LP. È presidente di Rosemary Mazanet LLC, presidente di R Mazanet LLC e responsabile scientifico di Columbia Care, Inc. La dottoressa Mazanet è anche nel consiglio di amministrazione di Oncternal Therapeutics, Inc. Nella sua carriera passata la dottoressa Mazanet ha occupato la posizione di amministratore delegato di Breakthrough Therapeutics LLC, direttore senior della ricerca clinica presso Amgen, Inc., responsabile della ricerca presso Argenis Capital Advisors LLC, partner presso Apelles Investment Management LP, venture partner presso Colt Ventures Ltd., direttore medico e vicepresidente esecutivo presso Galena Biopharma, Inc. e direttore scientifico e socio generale presso Oracle Partners LP. Il dottor Mazanet ha conseguito una laurea presso l'Università della Virginia e un dottorato presso la Perelman School of Medicine.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
21/09/2023 | 1 517 201 ( 0.36% ) | 546 192 $ | 29/02/2024 | |
28/06/2023 | 138 ( 0.00% ) | 1 283 $ | 29/02/2024 |
Posizioni attive di Rosemary Mazanet
Società | Posizione | Inizio |
---|---|---|
THE CANNABIST COMPANY HOLDINGS INC. | Director/Board Member | 07/09/2023 |
ONCTERNAL THERAPEUTICS, INC. | Director/Board Member | 27/01/2021 |
Oncolyze, Inc.
Oncolyze, Inc. BiotechnologyHealth Technology Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation. | Director/Board Member | - |
R Mazanet LLC | President | 01/05/2004 |
Rosemary Mazanet LLC | President | - |
Precedenti posizioni note di Rosemary Mazanet
Società | Posizione | Fine |
---|---|---|
Galena Biopharma, Inc.
Galena Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Galena Biopharma, Inc. is a biopharmaceutical company, which develops and commercializes hematology and oncology therapeutics that address unmet medical needs. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral sublingual tablets and Zuplenz oral soluble film. The company was founded by Craig Mello on April 3, 2006 and is headquartered in San Ramon, CA. | Chief Tech/Sci/R&D Officer | 07/11/2013 |
Cactus Ventures, Inc.
Cactus Ventures, Inc. Financial ConglomeratesFinance Cactus Ventures, Inc. operates as a blank check company. Cactus Ventures intends to locate and negotiate with a business entity for the merger of that target company into the company. The company was founded on October 6, 1997 and is headquartered in Carson City, NV. | Director/Board Member | 18/04/2013 |
Actinium Pharmaceuticals, Inc. /Old/
Actinium Pharmaceuticals, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Actinium Pharmaceuticals, Inc. provides development and commercialization of alpha particle immunotherapeutics services. It conducts research based on a patient position for the utilization of actinium-225 and bismuth-213. The company has offices in Oak Ridge, TN and Alexandria, VA. Actinium Pharmaceuticals was founded in 1993 and is headquartered in Florham Park, NJ. | Director/Board Member | 18/04/2013 |
Diabetes America, Inc.
Diabetes America, Inc. Medical/Nursing ServicesHealth Services Founded in 2004, Diabetes America has established a reputation in communities across Texas as a comprehensive health center and management program for individuals with diabetes, providing them with a team of physicians, dietitians, and certified diabetes educators all under one roof. Diabetes America's personalized education and lifestyle support provide patients with lifelong guidance for managing their diabetes and gives them the tools and support they need to take charge of their lives. | Director/Board Member | 17/09/2012 |
░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formazione di Rosemary Mazanet
University of Virginia | Undergraduate Degree |
Harvard Medical School | Doctorate Degree |
Perelman School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
AMGEN INC. | Health Technology |
ABEONA THERAPEUTICS INC. | Health Technology |
AKSYS LTD. | Finance |
Aziende private | 18 |
---|---|
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | Health Technology |
Acelerate, Inc.
Acelerate, Inc. BiotechnologyHealth Technology Acelerate, Inc. provides systems cell biology solutions. It address the problems of efficacy and toxicity with the cellular systems biology approach. The company was founded in 2004 and is headquartered in Pittsburgh, PA. | Health Technology |
Diabetes America, Inc.
Diabetes America, Inc. Medical/Nursing ServicesHealth Services Founded in 2004, Diabetes America has established a reputation in communities across Texas as a comprehensive health center and management program for individuals with diabetes, providing them with a team of physicians, dietitians, and certified diabetes educators all under one roof. Diabetes America's personalized education and lifestyle support provide patients with lifelong guidance for managing their diabetes and gives them the tools and support they need to take charge of their lives. | Health Services |
Actinium Pharmaceuticals, Inc. /Old/
Actinium Pharmaceuticals, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Actinium Pharmaceuticals, Inc. provides development and commercialization of alpha particle immunotherapeutics services. It conducts research based on a patient position for the utilization of actinium-225 and bismuth-213. The company has offices in Oak Ridge, TN and Alexandria, VA. Actinium Pharmaceuticals was founded in 1993 and is headquartered in Florham Park, NJ. | Commercial Services |
Amorcyte, Inc.
Amorcyte, Inc. Miscellaneous Commercial ServicesCommercial Services Amorcyte, Inc. provides cell therapy product development services. It focuses on developing cell therapeutics for cardiovascular disease. The company was founded by Andrew L. Pecora in 2004 and is headquartered in Allendale, NJ. | Commercial Services |
Cactus Ventures, Inc.
Cactus Ventures, Inc. Financial ConglomeratesFinance Cactus Ventures, Inc. operates as a blank check company. Cactus Ventures intends to locate and negotiate with a business entity for the merger of that target company into the company. The company was founded on October 6, 1997 and is headquartered in Carson City, NV. | Finance |
Galena Biopharma, Inc.
Galena Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Galena Biopharma, Inc. is a biopharmaceutical company, which develops and commercializes hematology and oncology therapeutics that address unmet medical needs. The company focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of the disease to the reduction of its debilitating side effects. Its products include Abstral sublingual tablets and Zuplenz oral soluble film. The company was founded by Craig Mello on April 3, 2006 and is headquartered in San Ramon, CA. | Health Technology |
Argenis Capital Advisors LLC
Argenis Capital Advisors LLC Investment ManagersFinance Argenis Capital Advisors LLC is an independent hedge fund manager headquartered in New York City. Founded in 2006, the firm provides investment advice to high net worth individual and institutional clients. | Finance |
Oracle Partners LP | |
The University of Pennsylvania Health System
The University of Pennsylvania Health System Miscellaneous Commercial ServicesCommercial Services The University of Pennsylvania Health System provides general patient care as well as medical education and research services. The company was founded in 1874 and is headquartered in Philadelphia, PA. | Commercial Services |
Breakthrough Therapeutics LLC | |
Colt Ventures Ltd.
Colt Ventures Ltd. Investment ManagersFinance Colt Ventures Ltd (Colt Ventures) is a venture capital firm founded in 2003 by Darren Blanton. The firm is headquartered in Dallas, Texas. | Finance |
Apelles Investment Management LP
Apelles Investment Management LP Investment ManagersFinance Apelles Investment Management LP is a hedge fund manager located in New York Cit | Finance |
Rosemary Mazanet LLC | |
The Cannabist Company Holdings, Inc. | |
Oncternal Therapeutics, Inc. | |
R Mazanet LLC | |
Oncolyze, Inc.
Oncolyze, Inc. BiotechnologyHealth Technology Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation. | Health Technology |